Natural leukocyte interferon-α therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-

Ayalew Tefferi, Darryl C. Grendahl

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Two patients with chronic-phase chronic granulocytic leukemia initially responded to recombinant interferon α-2a (rIFN-α-2a) but relapsed as a result of development of high-titer neutralizing antibodies to rIFN-α-2a. Both patients were subsequently treated with natural leukocyte IFN-α (IFN-α-n3), and one of the two patients achieved a durable second hematologic and cytogenetic remission. IFN-α-n3 may be considered for patients in whom antibody-mediated resistance to rIFN-α-2a develops.

Original languageEnglish (US)
Pages (from-to)231-233
Number of pages3
JournalAmerican journal of hematology
Volume52
Issue number3
DOIs
StatePublished - 1996

Keywords

  • CGL
  • Interferon antibodies
  • Interferon therapy

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Natural leukocyte interferon-α therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-'. Together they form a unique fingerprint.

Cite this